Short Interest in Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Rises By 1,083.3%

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a large increase in short interest in May. As of May 29th, there was short interest totaling 32,362 shares, an increase of 1,083.3% from the May 14th total of 2,735 shares. Based on an average daily trading volume, of 54,195 shares, the days-to-cover ratio is presently 0.6 days. Approximately 5.9% of the company’s shares are short sold.

Sigyn Therapeutics Price Performance

OTCMKTS:SIGY remained flat at $0.04 during trading hours on Wednesday. The company’s stock had a trading volume of 3,000 shares, compared to its average volume of 30,737. The company’s fifty day moving average is $0.04 and its 200 day moving average is $0.62. Sigyn Therapeutics has a 12-month low of $0.01 and a 12-month high of $5.00. The firm has a market capitalization of $100,330.00, a P/E ratio of -0.01 and a beta of -0.06.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.